Associate/Scientist, In Vivo Pharmacology

Earli exists to make cancer a benign experience. Earli does that by turning cancers against themselves: genetically forcing them to reveal themselves early, and then kill themselves – precisely and clearly distinguishable from benign lesions at early stages. Based on original technology from Stanford’s renowned Gambhir lab, Earli designs genetic constructs that are injected intravenously that turn cancer cells against themselves. These programmable synthetic promoter-reporter sequences “flip on” like light switches only in dysregulated cancer cells and turn them into "factories." The cancer is forced to produce either an epitope “docking station” for imaging agents, or a cytokine for immune system activation against the tumor. Thus, Earli’s platform enables immediate diagnosis and treatment of early cancers, rather than long-term observation that can lead to deadly metastatic recurrence.

Earli's synthetic target expression platform has evolved over five years of deep bioengineering. The system can now detect broad ranges of patient mutations, distinguish between malignant and benign lesions, and offer independence from often elusive natural biomarkers.

Who You Are

You share our same sense of dedication, scientific passion and entrepreneurial spirit

You work well in a fast-paced and extremely focused startup environment

You are not only smart, but clever and constantly think outside the box

You are able to make logical decisions in an instant when there is little time to evaluate

You are a natural communicator and relationship builder

You stay calm under high pressure and stress

You have the ability to multi-task in a serious way, with an extreme attention to detail

You become a representative of the core DNA of the company through who you are

The Position

Earli’s platform technology uses cancer-activated gene expression to usurp the dysregulated pathways that lead to malignancy. We are leveraging this platform for the creation of novel immuno-oncology therapeutic approaches to treat cancer. Your work will directly support the in vivo evaluation of these approaches. Within this context, you will:

Your Primary Responsibilities

Conduct, plan, perform, and analyze rodent in vivo experiments testing our cancer treatment products

Administer test agents to mice via multiple routes (IV, PO, IP, SC)

Assess tumor burden by caliper, bioluminescence, fluorescence and microCT measurements

Conduct rodent blood collections, surgeries, and necropsies

Contribute to Biochemical/Molecular analysis of tissues and plasma (i.e. qPCR, Luminex)

Maintain familiarity with current scientific literature

Depending on the level of experience, the candidate would be encouraged to lead their own projects and presenting data both internally and at conferences

Work independently and collaborate with scientific colleagues in support of team goals

Your Required Experience, Knowledge and Skill

Minimum of 3+ years of industry experience conducting rodent studies to determine efficacy of new therapies

Must have technical expertise in mouse handling, IV dosing, subcutaneous and orthotopic tumor cell implantation, tissue collection

Experience in contributing to cancer research questions is required

Experience with tissue culture and biochemical and/or molecular techniques is an advantage

Strong communication skills are required

Strong sense of scientific rigor, integrity, and curiosity are required

Ability to handle multiple projects simultaneously and meet aggressive project timelines

Highly organized with reliable time management skills

Ability to maintain detailed documentation

Ability to work in a team-oriented and fast-paced environment

Proficient with basic computer programs routinely used in a lab such as MS Word, Excel, and PowerPoint, GraphPad Prism

If interested in applying, please attach a CV or have a well-developed LinkedIn profile for us to be able to assess your background.

We look forward to hearing from you!